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The Pharmacological Audit Trail (PhAT) comprises a set of critical questions that need to be asked during
discovery and development of an anticancer drug. Key aspects include: (1) deﬁning a patient population;
(2) establishing pharmacokinetic characteristics; (3) providing evidence of target engagement, pathway
modulation, and biological effect with proof of concept pharmacodynamic biomarkers; (4) determining
intermediate biomarkers of response; (5) assessing tumor response; and (6) determining how to
overcome resistance by combination or sequential therapy and new target/drug discovery. The questions
asked in the PhAT should be viewed as a continuum and not used in isolation. Different drug
development programmes derive different types of beneﬁt from these questions. The PhAT is critical
in making go-no-go decisions in the development of currently studied drugs and will continue to be
relevant to discovery and development of future generations of anticancer agents.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Molecularly targeted drugs have become an integral compo-
nent of the treatment of cancer patients over the last three
decades and their importance continues to increase. There have
been successes where targeted agents have shown beneﬁt in
disease subtypes such as melanoma (vemurafenib [1]) and renal
cancer (sorafenib [2]) where conventional chemotherapy had close
to no efﬁcacy. Molecular therapeutics have also added incremental
patient beneﬁt for diseases such as diffuse B-cell lymphoma
(rituximab [3]) where chemotherapy was already of proven
beneﬁt. However, despite successes, there have been many failures
and there is a distinct feeling in the oncology research community
that the full potential of molecularly targeted approaches has not
yet been realised. Many failures of novel anticancer drugs to meet
endpoints in phase III studies have led to an economic model of
drug discovery and development that is unsustainable to the
pharmaceutical companies [4–6] and to pricing of drugs that
will often be out of reach for healthcare systems and cancer
patients [7].
The Pharmacological Audit Trail (PhAT) is based on addressing
essential questions relating to biomarkers (Fig. 1A) at the appropriateInc. This is an open access article u
ncer Therapeutics Unit, The
SM2 5NG, UK. Tel.: þ44 (0)
man).stages of drug development, aiming to maximize our chances of
success [8–10]. It is designed to help researchers in evidence-based
decision-making at various points in the life cycle of drug discovery
and development (Fig. 1B).2. Population identiﬁcation for targeted drugs
Many drug discovery campaigns target protein products of
speciﬁc genetic alterations linked to a tumor type or a subset of
patients with poor prognosis within a cancer type. Thus, before the
initiation of a ﬁrst-in-human clinical trial there is often a bio-
logically deﬁned patient population. Clear examples include BRAF
mutations in melanoma [11] or HER-2 ampliﬁcations in breast
cancer [12]. An extension to this is to include the drugs that target
an aberrant pathway downstream of a pre-speciﬁed genetic
alteration, such as MEK inhibitors used in the setting of melanoma
driven by BRAF mutations [13]. However, this approach does not
always lead to ﬁnding populations of patients with mutant
oncogenes that are likely to respond to treatment; for example,
PIK3CA mutations do not exclusively predict response to mamma-
lian target of rapamycin (mTOR) inhibitors [14]. Nevertheless,
mutation and ampliﬁcation status of tumors are increasingly being
seen as critical to regulatory approval (Table 1).
The availability of affordable hotspot mutation [15,16] and next-
generation sequencing platforms [17] have made clinical testing of
speciﬁc target-based hypotheses possible even in early-stage clinicalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. The pharmacological audit trail (PhAT). (A) The six crucial aspects of the pharmacological audit trail. (B) The relationship of the PhAT to the various phases of the life
cycle of an anticancer drug. The red lines indicate ‘checkpoints’ between different phases of drug development where go-no-go decisions are made.
U. Banerji, P. Workman / Seminars in Oncology 43 (2016) 436–445 437trials. This has led to the possibility of conducting ‘basket’ clinical trials
where subpopulations of patients with a speciﬁc mutation can be
tested irrespective of their tumor type [18]. In addition to DNA
mutations, protein expression can also be used to deﬁne tumor
subtypes likely to respond to treatment. As previously noted, HER-2
ampliﬁcation has been used to deﬁne patients likely to respond to
HER-2–targeting therapy and this can be detected by overexpression of
the protein in cancer cells.
Immunotherapy has made huge advances in the last decade
and more recently programmed death receptor ligand-1 (PDL-1)
expression [19] is currently being used to stratify patient groups
entering clinical trials of anti–PDL-1 antibodies [20]. Of recent
interest, the evaluation of unexpected responders in early phase
clinical trials (sometimes called n¼1 studies) has led to theretrospective study of determinants of sensitivity to targeted
anticancer drugs [21].
To help deﬁne and validate a patient population biomarker
before the start of a ﬁrst-in-human clinical trial, various approaches
have been tried. The use of large (4500) cancer cell line panels is
now feasible. This approach has been retrospectively validated by
identifying patient populations with, for example, BRAF or EGFR
mutations that are predictive for the activity of BRAF or EGFR
inhibitors, respectively, and remains a promising approach. How-
ever, prospective validation of new subgroups of patients suggested
by this approach is needed [22]. Other methodologies include use of
mRNA gene expression signatures; examples include RAF or RAS-
like signatures [23,24], which have been proposed and are currently
being used in clinical trials [25]. The use of established cancer cell
Table 1
Licensed targeted anticancer drugs, their targets, and tests done to deﬁne
sensitivity or resistance to these agents.
Drug Target Test
Imatinib c-KIT KIT mutations
Trastuzumab HER-2 HER-2 IHC, HER-2 FISH
Lapatinib HER-2 IHC, HER-2 FISH
T-DM1 HER-2 IHC, HER-2 FISH
Pertuzumab HER-3 HER-2 IHC, HER-2 FISH
Erlotinib EGFR EGFR mutations
Afatinib EGFR mutations
Dabrafenib BRAF BRAF mutations
Vemurafenib BRAF mutations
Trametenib MEK BRAF mutation
Crizotinib ALK ALK rearrangement FISH
Cetuximab EGFR KRAS mutation
Tamoxifen ER Estrogen receptor IHC
Rituximab CD20 CD-20 IHC
FISH ¼ ﬂuorescence in situ hybridization; IHC ¼ immunohistochemistry.
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questioned, and the use of patient-derived xenografts [26] and
alternative models such as organoid cultures and patient ‘avatar’
models have been hypothesized to better reﬂect patients’ tumors
[27].
In rare instances, biomarkers have been introduced into pre-
scribing guidelines after the drug has been licensed, as was done
when KRAS mutation status was found to determine resistance to
cetuximab in the setting of colorectal cancer [28]. However, there
are clear examples of targeted drugs that have been licensed
without a link to a speciﬁc biomarker for the activity of the drug,
as in the case of histone deacetylase (HDAC) inhibitors used to
treat cutaneous T-cell lymphoma [29], or the administration of
vascular endothelial growth factor receptor (VEGFR) inhibitors in
renal cancer [30].
While appreciating that many drug development programs will
have different features, the deﬁnition of a patient subgroup likely
to respond to treatment is a critical early step in all cases. Multiple
responses may be demonstrated in speciﬁed populations, even
early in phase I, as was the case for BRAF mutations predicting
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Fig. 2. Pharmacokinetics in the PhAT. The two main questions asked using PK analysis in
the umbrella of pharmacokinetics and their clinical importance are also shown.predicting response to poly ADP ribose polymerase (PARP) inhib-
itors [31]. If predictive biomarker assays can be tested in phase I
and reﬁned in phase II studies, they are more likely to be used as
companion diagnostics in phase III studies and the post-
registration setting.3. Pharmacokinetics
Pharmacokinetic (PK) studies are essential in drug develop-
ment, predominantly adding value in early-stage studies. First,
attaining a PK exposure in humans that causes anticancer activity
in preclinical models plays an important part in go-no-go decisions
during phase I studies. Bench-marking human PK to preclinical
models is now routine practice, and we have used this approach to
evaluate AKT, mTOR, HSP90, and HDAC inhibitors at our institution
[32–35]. Second, PK studies can help clarify toxicity proﬁles in
early phase development, especially by correlating PK proﬁles with
dose-limiting toxicities. Some drugs have toxicities related to early
Cmax (the maximal concentration achieved in plasma), as in the
case of serous retinopathy observed with MEK inhibitors [36,37],
or hyperglycemia, as observed with AKT inhibitors [35,38]. Adjus-
ting the dose of the drug such that the Cmax falls below levels that
cause unacceptable toxicity is a critical aspect of phase I studies.
Third, PK characterization is essential for determining the schedule
of oral anticancer agents. For example, the allosteric mTOR
inhibitor everolimus has a half-life of approximately 26 hours
and is administered once daily [39], while mTORC1/2 kinase
inhibitors such as AZD2014 have a half-life of approximately
3 hours and are administered twice a day [40]. Fourth, PK studies
are also critical to determine dosing recommendations for use of
the drug in relation to the consumption of food and concomitant
medications. For example, plasma concentrations of lapatinib can
be signiﬁcantly higher when taken with food, and this may have
implications for interpreting toxicity and efﬁcacy [41]. Fifth,
because targeted drugs are often administered orally, PK drug
interaction studies are important due to their metabolism by
CYP3A4 [42].
Therapeutic drug monitoring (TDM) uses PK measurements to
determine efﬁcacy and toxicity in routine clinical practice in areas
such as anti-epileptic or anticoagulation therapy; however, its useCmax-related toxicity
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to growth delay in 
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early phase drug development are highlighted. Multiple parameters studied within
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where cancer has become a disease that requires chronic treat-
ment, such as imatinib for the treatment of chronic myeloid
leukaemia [45], TDM will become increasingly relevant [46].
As the above examples demonstrate, PK assessment is essential
to decision-making in phase I studies and also in preclinical
discovery and development (Figs. 1B and 2). On rare occasions
PK studies can play a role in drug development as late as the post-
marketing phase.4. Pharmacodynamic and proof of mechanism biomarkers
Use of pharmacodynamic (PD) biomarkers, including proof of
mechanism (POM) endpoints, is a critical aspect of the PhAT in the
development of targeted agents (Fig. 3). It is extremely important
to demonstrate modulation of the target by the drug, and also to
ensure that target engagement results in downstream perturba-
tion of the intended biochemical pathway and the subsequent
biological phenotype.
The ﬁrst question to be asked is what is the best POM
biomarker? An ideal biomarker is one that measures changes in
the target itself or in proteins that are in close functional proximity
to the target. An example of studying changes in the target itself is
quantifying phospho-AKT (p-AKT) while evaluating an allosteric
AKT inhibitor such as MK2206 where the POM biomarker is a
phosphorylation site on the target [38]. An example of a proximal
mechanistic biomarker is quantifying the accumulation of dehy-
drocorticosterone while evaluating the CYP17:C17,20 lyase inhib-
itor abiraterone [47]. A more commonly used strategy includes the
measurement of protein biomarkers ‘downstream’ of the intended
target such as quantiﬁcation of p-ERK while studying MEK
inhibitors including trametinib and selumetinib [36,48].
The second question to be asked in developing PD endpoints is
what is the best tissue in which to study the biomarker? Clinical
trials often use surrogate normal tissues at early dose levels in
phase I studies because it may be considered unethical to take
tumor biopsies from patients at dose levels that are unlikely to
show PD effects. Normal tissue also has the advantage of beingPharmacodynamic
Proof of Mechanism (POM)
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Fig. 3. Pharmacodynamics in the PhAT. Pharmacodynamic biomarkers can be concep
questions, tissues studied, and platforms used to study them are shown.able to be sampled repeatedly. Examples of normal tissue used in
POM-PD studies include measuring p-AKT in platelet rich plasma
while studying PI3K inhibitors [49,50], or using peripheral blood
mononuclear cells to measure histone acetylation or p-ERK levels
when evaluating HDAC [34,51] and MEK [36] inhibitors, respec-
tively. Normal cells extracted from blood have the advantage of
allowing PD endpoints and plasma drug levels to be determined
simultaneously, thus making PK-PD modeling particularly rele-
vant. Examples of PK-PD modelling using combined PK and PD
determinations in blood to recommend a phase II dose include the
use of p-S6 or protein acetylation in peripheral blood mononuclear
cells in the case of mTOR or HDAC inhibitors, respectively [32,34].
However, blood-derived POM-PD can be criticised for showing
positive PD effects even if a drug has limited penetration outside
the vascular space. Assessing hair follicles circumvents this prob-
lem. Histone acetylation or p-PRAS40 quantiﬁcation in hair fol-
licles while evaluating HDAC [34,51] and AKT [38] inhibitors,
respectively, and punch skin biopsies to quantify p-ERK when
evaluating MEK inhibitors [37] have been used successfully in ﬁrst-
in-human studies.
The use of normal tissues as surrogates can be problematic
because they may not represent rapidly proliferating tumor tissue
and lack the activating mutations that drive cancer. Hence, pre-
and post-treatment tumor biopsies are the gold standard for
evaluating mechanistic biomarkers to examine PD changes in the
target malignant tissue in question [52]. Pre- and post-treatment
tumor biopsies are often done in the last few cohorts of a dose-
escalation phase I study and have been successfully used to
support recommendation of phase II doses of BRAF [1], MEK
[48], PI3K [49], and AKT [35,38] inhibitors. Tumor biopsies serve
to study cancer cells, but can also be used to study the stroma.
Tumor inﬁltration by speciﬁc subsets of lymphocytes (CD8þ) could
be used as POM biomarkers while evaluating immunotherapeutic
agents such as PDL-1 antibodies [20].
Pre- and post-treatment tumor biopsies are not without their
own problems. Although considered safe in the literature [53],
they are invasive procedures and have the potential for complica-
tions such as bleeding. Biopsies from multiple sites of resected
tumors have shown considerable genetic heterogeneity [54], ands and PhAT
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effects. In some instances, it is possible to circumvent being misled
by intra-tumoral heterogeneity by using imaging to assess POM-
PD biomarkers. An example is the use of 89Zr-labeled trastuzumab
positron emission tomography (PET) scans to detect degradation of
HER-2 caused by the HSP90 inhibitor AUY922 or luminespib [55].
The third important question asked in relation to PD assays is
how much target inhibition is enough? Because tumor biopsies are
not done in sufﬁcient numbers across all dose levels, it may not be
possible to demonstrate a dose-response relationship in tumor
tissue; instead, this is commonly done in normal tissue where it is
sometimes possible to demonstrate a sigmoid shaped curve in
which no additional signiﬁcant biomarker modulation occurs upon
increasing drug doses once a plateau is reached. Examples include
HSP70 induction while evaluating HSP90 inhibitors [33] (where, in
fact, depletion of protein clients is more important) and p-ERK
inhibition while evaluating MEK inhibitors [36], but data from
normal tissue identifying a plateau in POM-PD response should
not be the sole criterion used to halt dose escalation, as PD
changes in normal tissue may not mimic tumor tissue. In some
early-phase trials where it has been possible to biopsy multiple
patients (for example, while evaluating BRAF inhibitors such as
vemurafenib in the setting of melanoma), correlation of the degree
of biomarker modulation (in this case p-ERK inhibition) to tumor
response has been achieved [56]. Quantitation of PD effects is
important, especially where 495% of the signaling output must
be inhibited to have the desired effect, as with many kinase
inhibitors.
It is important to discuss the possible downside of conducting
PD biomarker studies. For drugs that target a relatively large
number of kinases, the ﬁnal activity of a drug might not be related
to the POM-PD biomarker being studied. For example, phase I
trials of sorafenib, initially developed as a RAF inhibitor, success-
fully demonstrated reduction in p-ERK levels [57]. However, it
proved to be sorafenib’s anti-angiogenic activity that led to
approval for renal cell cancer [2], acting on VEGF and other targets;
trials of sorafenib in BRAF mutation-driven tumors, such as
melanoma, were negative [58]. As discussed in other articles in
this issue of Seminars in Oncology, the use of POM-PD biomarkers
does entail careful technical validation, which adds additional
costs [59,60]. However, the cost of failure of late-phase develop-
ment in clinical trials is very high, and we believe that the increase
in cost resulting from use of PD biomarkers in early drug develop-
ment is entirely justiﬁed as they could prevent drugs not
modulating target from progressing to expensive phase II and III
trials [61]. For example, the PARP inhibitor iniparib failed to
meet its endpoint in a phase III study and, regrettably, it was
only at this stage that its mechanism as a PARP inhibitor was
questioned, which is something that should have been discovered
in phase I [62].5. PD proof of concept biomarkers
The ultimate effect of inhibiting a cancer target is usually
related to modulating one of the hallmark traits of the cancer
cells [63]. Proof of concept biomarkers thus predominantly focus
on assessing functional biological consequences of inhibiting
targets in tumor tissue (Fig. 3).
5.1. Proliferation
Examples of PD biomarkers for proof of concept have included
assessing proliferation through use of Ki67 determined by immu-
nohistochemistry [64]. As an example, use of this biomarker has
accompanied POM-PD studies in a clinical trial of trametinib,where tumor Ki67 effects were measured to show the functional
consequence of inhibiting p-ERK [48]. In later stage phase II
studies, changes in Ki67 can be used as a surrogate measure to
determine clinical efﬁcacy; for example, it has been employed in
randomized phase II studies of fulvestrant to demonstrate the
efﬁcacy of two doses of the drug [65]. Other methods of determin-
ing proliferation include the use of imaging modalities like FLT-PET
[66], where it has been possible to correlate immunohistological
markers of proliferation such as Ki67 to SUVmax values. Post-
treatment FLT-PET changes in rapidly proliferative malignancies
like lymphoma not only conﬁrm reduction in DNA synthesis and,
hence, proliferation as a consequence of treatment, but could also
be used as an early predictor of complete response [67].5.2. Metabolism
There are multiple imaging platforms that detect changes in
metabolism caused by targeted anticancer agents. FDG-PET has
been extensively used to study glucose metabolism while evaluat-
ing anticancer drugs [68]. Changes in glucose metabolism are
usually not directly linked to the mechanism of action of the drug,
but rather a downstream consequence of inhibiting the intended
target. Examples include the FDG-PET changes observed in gastro-
intestinal stromal tumors (GIST) following treatment with imati-
nib, which inhibits c-KIT [69], or the alterations within tumors in
patients with melanoma following treatment with the BRAF or
MEK inhibitors vemurafenib [70] and trametinib [48], respectively.
Magnetic resonance spectroscopy has been used to observe
changes in phosphocholine and, more recently, lactate levels that
could be used to evaluate drugs targeting metabolism such as
BRAF, PI3K, and HSP90 and HDAC inhibitors [71].5.3. Angiogenesis
Dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) studies have demonstrated changes in angiogenesis
during evaluation of anti-angiogenic agents such as bevacizumab
[72,73] and sorafenib [74,75]. These are examples of studying
downstream POC biomarkers of drugs that target VEGF or VEGFR.5.4. DNA damage and apoptosis
DNA damage and apoptosis are important endpoints of many
targeted agents. For example, DNA damage caused by PARP
inhibitors has been studied using phosphorylation of γH2AX in
hair follicles [31]. Multiple 18F-labeled PET probes such methyl-
malonic acid (MMA) [76], caspase-3 [77], and annexin [78,79] are
under clinical evaluation to quantitate and determine the distri-
bution of apoptosis within tumors before and after drug treatment.
The expectations for and interpretation of these biomarker
endpoints depends on the setting in which they are used. In phase
I studies, biomarkers for proof of concept are often used to
accompany POM-PD biomarkers where it is critical to determine
that target modulation has led to functional consequences in the
tumor. Examples discussed above in this section include evaluat-
ing the degree of modulation of proliferation (Ki67, FLT-PET),
apoptosis (cleaved caspase-3), angiogenesis (DC-MRI), or metabo-
lism (FDG-PET). In later, phase II–III studies these biomarkers are
often correlated to clinical outcomes such as response or time to
progression. In this setting there has been some success, such as
the use of FDG-PET predicting early response to treatment in
speciﬁc subtypes of lymphoma [80,81]. Although widely used,
such biomarkers should not be the sole criteria for decision-
making [82].
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This is an area of emerging importance in the PhAT. Having an
early insight into whether a patient will beneﬁt from treatment or
not is important as it empowers the treating clinician to change
treatment early, improving patient outcomes, reducing unneces-
sary toxicity experienced by the patient, and improving efﬁciency
in healthcare delivery.6.1. Tumor-speciﬁc circulating biomarkers
Prostate-speciﬁc antigen (PSA) has been used to follow
response in prostate cancer, as there is often ‘bone only’ disease,
making imaging to delineate clinical outcome challenging. An
early drop in PSA has been shown in some clinical trials to predict
survival [83], though this is not universally accepted [84]. CA-125
has been conventionally used to follow treatment outcomes in
ovarian cancer; however, tests such as CA-125 have been validated
in patients receiving cytotoxic chemotherapy where rapid tumor
regression is seen [85]. More sophisticated analysis is required to
interpret data related to CA-125 when evaluating molecularly
targeted agents such as tamoxifen where rapid tumor regression
may not be seen [86].6.2. Circulating tumor cell count and circulating free DNA
Circulating tumor cell (CTC) counts have been used to assess
early response to treatment of prostate cancer [87]. CTCs have
many advantages, including the ability to sample multiple time
points, and use in a disease where the only site of metastasis is
bone, where conventional imaging is difﬁcult [88]. Quantiﬁcation
of circulating free DNA (cfDNA) has been linked to tumor burden
and prognosis in patients with metastatic cancers entering phase I
studies [15], and it is being studied further to determine whether
changes in cfDNA levels can be used as an early biomarker of
response or resistance in breast cancer [89].Intermediate endpoints
reassessment of diseas
Response














Fig. 4. Intermediate endpoints of response and reassessment of disease at progression. S
tissue used and tests done while evaluating these biomarkers are shown.6.3. Imaging techniques
FDG-PET has provided insights into early response to targeted
treatment such as imatinib [90] for the treatment of GIST or in
Hodgkin’s lymphoma with chemotherapy [81]. Early changes in
cell number within a tumor can be studied using diffusion-
weighted MRI [91], and this is currently being validated to study
response in tumors such as ovarian [92], prostate [93], and colon
cancer [94].
Overall, intermediate endpoints of response or resistance to
treatment are thus critical to drug development (Fig. 4). However,
they need extensive validation, often in a large number of patients.
Also of note, care should be taken to differentiate intermediate
biomarkers of response from prognostic biomarkers.7. Reassessment of molecular alteration at disease progression
The use of targeted anticancer agents in patients with tumors
that have been genetically characterized has led to considerable
success; however, it has increasingly become evident that acquired
resistance is inevitable. For example, resistance occurs within 6–12
months of treatment with vemurafenib for the treatment of BRAF-
mutant melanoma [95] or geﬁtinib for the treatment of EGFR-
mutant lung cancer [96].
Obtaining tumor biopsies at progression following initial
response has given researchers insights into mechanisms of
resistance. For example, biopsies obtained after patients with
melanoma became resistant to BRAF inhibitors were compared
to pretreatment samples, and these revealed (among other
changes) the presence of new MEK1 and MEK2 mutations [97].
Sampling circulating cells has the advantage that it can be
repeated at many time points. CTCs have many applications [88].
In addition to quantifying them, it is possible to detect novel
mutations that cause resistance to targeted treatment, for exam-
ple, T790M EGFRmutations were found in CTCs from patients with
EGFR-mutant lung cancer receiving EGFR-targeted treatment [98].
Serial blood samples to study cfDNA is an important approach, and
can be used in early phase clinical trials [15] in a variety of tumor of response and 
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U. Banerji, P. Workman / Seminars in Oncology 43 (2016) 436–445442types for detecting new mutations after resistance has appeared
following treatment with chemotherapy or targeted anticancer
agents (Fig. 4) [89,99].
Growing tumor xenografts [100,101] from patient biopsies
allows parallel treatment of the xenografts while the patient is
undergoing treatment. These tumor xenograft models, variously
called patient-derived xenografts (PDX) or avatar models, are
being used to elucidate mechanisms of resistance in patients
[27], and their use will be more widespread in the future.
Thus, reassessment of tissue, cells, and circulating cells and DNA
from human tumors is critical to understand the mechanism of
resistance and plan further treatment. Technological advances now
allow us to sample cfDNA representing tumor in blood samples,
which could, in the future, enable us to change treatment or propose
combination therapy in real time.8. Reversal of resistance by new drugs or combination therapy
Reassessment of tumors when a patient has become clinically
resistant to the treatment had led to the identiﬁcation of alter-
ations within the original target. This information can be success-
fully exploited, as is exempliﬁed in the case of detection of ‘gate
keeper’ T790M EGFR mutations occurring following treatment
with geﬁtinib [98]. These observations led to the development of
irreversible EGFR inhibitors such as afatinib [102] and, more
recently, the development of the T790M EGFR-speciﬁc inhibitor
AZD9291 [103].
While analysis of mutations can help us understand mecha-
nisms of resistance, cross talk and altered feedback loops in signal
transduction networks that are not a consequence of mutation can
also be a mechanism of resistance [104]. An example of the clinical
importance of feedback loops is EGFR phosphorylation following
BRAF inhibition in BRAF-mutant colon cancer. This was brought to
light with elegant experiments using shRNA screens in the
presence of a BRAF targeted drug as a means of identifying
synthetic lethality [105]. This mechanism of resistance could be
circumvented by combining BRAF and EGFR inhibitors, as currently
being evaluated in hypothesis-testing clinical trials.
Also of importance is understanding transient, reversible changes
in signalling following the exposure to a drug. For example, transient
SOX-10–mediated transforming growth factor-beta (TGF-β) signalingReversal of resista
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siRNA/shRNA screens 
in presence of target 






• Re-treat with same drug
• Treat sequentially with e
• Treat in combination wit
• New drugs on the same
• Develop drugs on new t
Fig. 5. Reversal of resistance and PhAT. Resistance to targeted anticancer drugs can b
analysis of the data and understanding the mechanisms of resistance, methods of clinicin melanomas can follow treatment with BRAF and MEK inhibitors;
this could theoretically be circumvented by re-introducing the drug
after a ‘drug holiday’ [106]. Interestingly, high throughput platforms
now being used have correctly predicted resistance even before such
events have occurred in the clinical development of the drug. For
example, over-expression of a large panel genes in a V699E mutant
melanoma cell line to look for genes conferring resistance to BRAF
inhibitors led to the elucidation of the mechanism of COT-mediated
MEK activation [107,108], subsequently overcome by combinations of
BRAF and MEK inhibitors [109].
Combining anticancer agents is an attractive proposition to
overcome resistance but there may be considerable challenges due
to combinatorial toxicity [110]. Careful attention to detail of
scheduling and dose, using all aspects of the PhAT, are necessary
to fully realize the clinical promise of innovative combinations
(Fig. 5) [111].9. Future of the PhAT
The PhAT is a conceptual framework that we developed which
codiﬁes a series of biomarker-driven questions that are used to
support pharmacologic understanding and evidence-based deci-
sion-making in drug discovery and development [8–10].
Over the last three decades, the focus of cancer drug discovery
has changed substantially from the development of one-size-ﬁts-all
cytotoxic chemotherapy agents, to personalized or precision molec-
ular targeted agents that modify oncogenic signal transduction and
epigenetic control mechanisms, and more recently to immunother-
apy and antibody drug conjugates. The development of all targeted
treatments has beneﬁted from asking the critical questions detailed
in the PhAT. Each category of drugs and individual agents presents
different unique challenges and rewards as well as speciﬁc technical
differences when using the PhAT.
Newer drugs, however, like immune checkpoint modulator
antibodies, notably anti-CTLA4, PD-1, and PDL-1, have resulted in
clinical response in an increasingly wide range of tumor types
without the use of speciﬁc patient-selection biomarkers for
example. Further, clinical trials have not reported widely on PK
and PD of these agents. Note that this is not a failure of the PhAT,
but reﬂects the speed of development of these agents, which have
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cant toxicity; POM and POC biomarkers could be used to further
reﬁne dosing and schedules in the future. Biomarkers that predict
response will rationalize giving such drugs to speciﬁc subgroups of
patients who will gain the most beneﬁt.
Drug discovery and development in oncology will continue
to respond to the understanding of the biology of cancers.
Hand-in-hand with developing drugs that block oncogene addic-
tion and target very small populations of patients with speciﬁc
genetic abnormalities such as ALK inhibitors, drug discovery
efforts are re-discovering the virtues of targeting a range of
mechanisms that are important in cancer such as cell cycle check
points (CDK4/6, CHK1), DNA repair (PARP, ATR), and epigenetic
regulation. This group of targets and drugs will bring its own set of
challenges of identifying patient populations and choosing the
correct PD biomarkers to help deﬁne dosing and schedules.
It is very important to view the PhAT as a continuum of critical
questions in the life cycle of an anticancer drug (Fig. 1B). Often
speciﬁc aspects, such as cost, stimulate passionate arguments
[59-61]. Further, while scientiﬁc rigor should not be compromised,
the degree of validation needed for PD assays in early-phase
clinical trials should be balanced with the important information
acquired. Extent of validation should not be an obstacle for using
these tests [112-115], when data can be further conﬁrmed in
increasing detail in future trials. Fit-for-purpose validation will
be key in the future. The fact is that different aspects of the PhAT
will offer more important information in some drug discovery
projects than others, but that should not stop the oncology
community from asking all the relevant questions. The relation-
ship between different phases of clinical trials, ie, phase I/II/III, is
also likely to evolve. There have been provisional licences granted
to anticancer drugs based on phase II data, and the questions
currently posed later in the PhAT are now being asked earlier than
before. Reviewing the progress and development in the past three
decades and taking stock of the current trends, we believe the
PhAT is and will remain relevant and important irrespective of the
direction cancer drug discovery and development takes in the
future.
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